Our Mission Statement
This is Photoshop's version of Loremer Ipsn gravida nibh vel velit auctoregorie sam alquet.Aenean sollicitudin, lorem quis bibendum auci elit consequat ipsutis sem nibh id elit.
Follow Us
About Us – Transcell
page-template,page-template-full-width,page-template-full-width-php,page,page-id-5969,mkd-core-1.0,highrise-ver-1.0,,mkd-smooth-page-transitions,mkd-ajax,mkd-grid-1300,mkd-blog-installed,mkd-header-vertical,mkd-sticky-header-on-scroll-up,mkd-default-mobile-header,mkd-sticky-up-mobile-header,mkd-dropdown-slide-from-bottom,mkd-dark-header,mkd-full-width-wide-menu,mkd-search-dropdown,mkd-side-menu-slide-from-right,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

About Us

The Make It Happen Team


To translate adult stem cell technology prowess into cancer clinical reality


  1. To discover druggable first-in-class molecules against undruggable and challenging targets in Cancers
  2. To utilize proprietary progenitor cellular platform technology as a tool addressing ethically compliant in vitro human physiology mimicking models – Alternatives to animals in experimental science and research
  3. To utilize proprietary repository derived off-shelf vector technology for CAR-T cell therapies


In June 2017, Transcell shareholders agreed to focus it’s disruptive drug discovery pursuits in Oncology vertical with the team’s early breakthrough data on certain druggable molecules discovered, as a spin-out (Transcell Oncologics). The research on predictive real-time donor and patient-based progenitor cellular platforms dates back to 2013 while access to nature-inspired novel macrocyclic small molecules/toolbox to 2014


  1. Current drugs in the market do not cure Cancers
  2. Long and irrational drug discovery process for Oncology


Develop all new rational nature-inspired complex architectural, scalable synthesis based, macrocyclic small molecules toolbox and hunt for druggable, selective killers of cancer stem cells

Pursue multi-target activity spaces between druggable molecules and cancer stem cells to develop investigational new drugs (INDs) for cancers